Nuzum Charles Lee Sr
Known title: DirectorCIK: 0001346421
Nuzum Charles Lee Sr's purchase track record
Nuzum Charles Lee Sr has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/20/2022 | AGPU | $62K | +54.1% | +11.1% | +1.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AGPU | ▲ Buy | Grant | 733 | $0 | 10/1/2026 | View on chart |
| AGPU | ▲ Buy | Grant | 2,420 | $0 | 7/1/2026 | View on chart |
| AGPU | ▲ Buy | Grant | 14,082 | $0 | 4/20/2026 | View on chart |
| AGPU | ▲ Buy | Grant | 64,680 | $0 | 9/9/2025 | View on chart |
| AGPU | ▲ Buy | Grant | 3,268 | $0 | 4/5/2024 | View on chart |
| AGPU | ▲ Buy | Grant | 2,605 | $0 | 10/2/2023 | View on chart |
| AGPU | ▼ Sell | Open Market | 10,000 | $30K | 9/25/2023 | View on chart |
| AGPU | ▲ Buy | Grant | 3,773 | $0 | 7/3/2023 | View on chart |
| AGPU | ▲ Buy | Grant | 25,499 | $0 | 4/3/2023 | View on chart |
| AGPU | ▲ Buy | Grant | 53,539 | $0 | 1/25/2023 | View on chart |
| AGPU | ▲ Buy | Grant | 172,150 | $0 | 1/3/2023 | View on chart |
| AGPU | ▲ Buy | Grant | 23,147 | $0 | 10/3/2022 | View on chart |
| AGPU | ▲ Buy | Grant | 44,704 | $0 | 7/1/2022 | View on chart |
| AGPU | ▲ Buy | Open Market | 200,000 | $62K | 5/20/2022 | View on chart |
| AGPU | ▲ Buy | Grant | 8,530 | $0 | 3/31/2022 | View on chart |
| AGPU | ▲ Buy | Grant | 43,775 | $0 | 1/4/2022 | View on chart |
| AGPU | ▲ Buy | Grant | 6,265 | $0 | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Axe Compute Signs $266M in AI Contracts, Exits Cancer Business
Axe Compute has secured over $266 million in new AI infrastructure contracts since mid-August. The company is also selling its cancer business to fully transition into an AI-focused entity. These moves mark a significant strategic shift for the stock, which trades with high beta and has a wide 52-week range.
Axe Compute Signs $266M in AI Contracts, Exits Cancer Business. Axe Compute has secured over $266 million in new AI infrastructure contracts since mid-August. The company is also selling its cancer business to fully transition into an AI-focused entity. These moves mark a significant strategic shift for the stock, which trades with high beta and has a wide 52-week range.